Heparin-induced thrombocytopenia and COVID-19
Heparin-induced thrombocytopenia (HIT) has not been included as a possible cause of thrombocytopenia in Coronavirus Disease 2019 (COVID-19) patients. We report a case of HIT in a patient with COVID-19 treated with heparin. A 78-yearold man was admitted to our hospital for acute respiratory failure and acute renal failure due to SARS-CoV-2 infection; in intensive care unit, one 5000IU heparin dose (day 0, platelet count 305000/μL). On day 2, haemoglobin started to decrease and heparin was stopped. On day 10, platelet count was 153000/μL and 5000IU calcium heparin subcutaneously twice daily was started. The platelet further decreased, reaching 49000/μL on day 17, and the patient was investigated for suspected HIT: an IgG specific chemiluminescence test for heparin- PF4 antibodies was positive and a femoral DVT was found at ultrasound. Argatroban was started, platelet count increased without any bleeding and thrombosis complication. Our experience shows that HIT may develop in heparin treated COVID-19 patients and should be included among the possible cause of thrombocytopenia in such patients.
Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50:54-67. DOI: https://doi.org/10.1007/s11239-020-02134-3
Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020;191:148-50. DOI: https://doi.org/10.1016/j.thromres.2020.04.041
Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. DOI: https://doi.org/10.1016/j.thromres.2020.04.024
Voicu S, Bonnin P, Stépanian A, et al. High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients [published online ahead of print, 2020 May 29]. J Am Coll Cardiol. 2020;76:480-2. DOI: https://doi.org/10.1016/j.jacc.2020.05.053
Paranjpe I, Fuster V, Lala A, et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020;76:122-4. DOI: https://doi.org/10.1016/j.jacc.2020.05.001
Ayerbe L, Risco C, Ayis S. The association between treatment with heparin and survival in patients with Covid-19. J Thromb Thrombolysis. 2020;50:298-301. DOI: https://doi.org/10.1007/s11239-020-02162-z
Tal S, Spectre G, Kornowski R, Perl L. Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far? [published online ahead of print, 2020 May 12]. Acta Haematol. 2020;1-8. DOI: https://doi.org/10.1159/000508233
Marietta M, Ageno W, Artoni A, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. 2020;18:167-9.
Cosmi B. Current management of heparin-induced thrombocytopenia. Expert Rev Hematol. 2015;8:837-49. DOI: https://doi.org/10.1586/17474086.2015.1087845
Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin induced thrombocytopenia. Blood 1994;84:3691-9 DOI: https://doi.org/10.1182/blood.V84.11.3691.bloodjournal84113691
Jiang SQ, Huang QF, Xie WM, Lv C, Quan XQ. The association between severe COVID-19 and low platelet count: evidence from 31 observational studies involving 7613 participants. Br J Haematol. 2020;190:e29-e33. DOI: https://doi.org/10.1111/bjh.16817
Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759-65. DOI: https://doi.org/10.1111/j.1538-7836.2006.01787.x
Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e495S-e530S. DOI: https://doi.org/10.1378/chest.11-2303
Dragonetti D, Guarini G, Pizzuti M. Detection of anti-heparin-PF4 complex antibodies in COVID-19 patients on heparin therapy. Blood Transfus 2020; 18: 328.
Lingamaneni P, Gonakoti S, Moturi K, Vohra I, Zia M. Heparin-Induced Thrombocytopenia in COVID-19. J Investig Med High Impact Case Rep. 2020;8:2324709620944091. DOI: https://doi.org/10.1177/2324709620944091
Patell R, Khan AM, Bogue T, et al. Heparin induced thrombocytopenia antibodies in Covid-19 [published online ahead of print, 2020 Jul 13]. Am J Hematol. 2020;10.1002/ajh.25935. DOI: https://doi.org/10.1002/ajh.25935
Thachil J, Warkentin TE. How do we approach thrombocytopenia in critically ill patients?. Br J Haematol. 2017;177:27-38. DOI: https://doi.org/10.1111/bjh.14482
Zhang Y, Zeng X, Jiao Y, et al. Mechanisms involved in the development of thrombocytopenia in patients with COVID-19. Thromb Res. 2020;193:110-5. DOI: https://doi.org/10.1016/j.thromres.2020.06.008
Morena V, Milazzo L, Oreni L, et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med. 2020;76:36-42. DOI: https://doi.org/10.1016/j.ejim.2020.05.011
Warkentin TE, Sheppard JI, Linkins LA, Arnold DM, Nazy I. High sensitivity and specificity of an automated IgG-specific chemiluminescence immunoassay for diagnosis of HIT. Blood. 2018;132:1345-9 DOI: https://doi.org/10.1182/blood-2018-04-847483
- Abstract views: 551
- PDF: 235
- HTML: 0
Copyright (c) 2021 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.